Ziyi Xu

发表

Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application

F. Gao, Chen Zhang, C. Fu, 2020, Frontiers in Pharmacology.

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)

P. Xing, Junling Li, X. Hao, 2021, Thoracic cancer.

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis

P. Xing, Junling Li, Ziyi Xu, 2022, BMC cancer.

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

J. Ying, P. Xing, Junling Li, 2021, Thoracic cancer.

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression

P. Xing, Junling Li, X. Hao, 2022, Cancer management and research.

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA

J. Ying, P. Xing, Junling Li, 2022, Thoracic cancer.

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy

P. Xing, Junling Li, Jun Zhao, 2021, Thoracic cancer.

A Quantitative Metal-Encoded Conjugate Platform for Targeting Ligand Discovery.

A. Vegas, Ziyi Xu, Thomas Ireland, 2022, Bioconjugate chemistry.

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report

J. Ying, P. Xing, Junling Li, 2022, Frontiers in Oncology.

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

P. Xing, Junling Li, X. Hao, 2022, Journal of Cancer Research and Clinical Oncology.

Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

P. Xing, Junling Li, Le Wang, 2021, Evidence-based complementary and alternative medicine : eCAM.

Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives

P. Xing, Junling Li, X. Hao, 2023, Cancer Innovation.

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma

P. Xing, Junling Li, D. Ma, 2018, Thoracic cancer.

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Jun-ling Li, Ziyi Xu, Jun-Ling Li, 2019, OncoTargets and therapy.

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients

P. Xing, Junling Li, X. Hao, 2022, Cancer management and research.

可切除Ⅲa/N2期非小细胞肺癌治疗模式探讨

J. Ying, P. Xing, Junling Li, 2019, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

P. Xing, Junling Li, X. Hao, 2019, Targeted Oncology.

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

P. Xing, Junling Li, Yan Wang, 2020, Journal of Cancer Research and Clinical Oncology.

Targeting the RhoA-GEF-H1 pathway of mast cells attenuates experimental airway allergy.

Gui Yang, Li-Hua Mo, Pingchang Yang, 2023, Archives of biochemistry and biophysics.

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

P. Xing, Junling Li, X. Hao, 2021, Thoracic cancer.

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis

P. Xing, Junling Li, Le Wang, 2023, Chinese medical journal.

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

P. Xing, Junling Li, X. Hao, 2023, BMC Cancer.